Drug Guide
Diphenhydramine Hydrochloride
Classification
Therapeutic: Antihistamine, Antitussive
Pharmacological: First-generation H1 antihistamine, Muscarinic receptor antagonist
FDA Approved Indications
- Relief of allergy symptoms (rash, itching, watery eyes, runny nose, hay fever)
- Prevention and treatment of motion sickness
- Insomnia
- Cough suppression (antitussive)
Mechanism of Action
Diphenhydramine blocks H1 histamine receptors, reducing allergy symptoms; it also has anticholinergic and sedative properties, which contribute to its effect in motion sickness and sleep induction.
Dosage and Administration
Adult: 25-50 mg every 4-6 hours as needed, not exceeding 300 mg/day
Pediatric: 2-6 years: 6.25-12.5 mg every 4-6 hours (max 75 mg/day); 6-12 years: 25-50 mg every 4-6 hours (max 150 mg/day)
Geriatric: Use with caution, starting at lower doses due to increased sensitivity and risk of anticholinergic effects
Renal Impairment: Adjust dose based on severity, consult dosing guidelines
Hepatic Impairment: Use with caution; dose adjustments may be necessary
Pharmacokinetics
Absorption: Well absorbed from gastrointestinal tract
Distribution: Widely distributed; crosses blood-brain barrier
Metabolism: Hepatic, primarily by CYP2D6 and other liver enzymes
Excretion: Renal; unchanged drug and metabolites
Half Life: 2.4 to 9.3 hours, longer in the elderly
Contraindications
- Newborns and premature infants
- Liver failure
- Acute asthma exacerbation
Precautions
- Use with caution in elderly; may cause sedation, confusion, or anticholinergic effects
- May impair cognitive or motor performance
- Monitor for paradoxical excitation in children
Adverse Reactions - Common
- Drowsiness (Very common)
- Dizziness (Common)
- Dry mouth (Common)
- Constipation (Common)
Adverse Reactions - Serious
- Respiratory depression (Rare)
- Allergic reactions (rash, angioedema, anaphylaxis) (Rare but serious)
- Hallucinations, seizures (in overdose) (Rare)
Drug-Drug Interactions
- CNS depressants (additive sedation)
- Monoamine oxidase inhibitors (risk of anticholinergic effects)
- QT prolonging drugs
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for effectiveness (relief of allergy symptoms, sleep quality, cough suppression) and adverse effects (sedation, anticholinergic effects)
Diagnoses:
- Risk for injury due to sedation or dizziness
- Impaired sleep pattern
Implementation: Administer with food if GI upset occurs, monitor for CNS depression, educate about avoiding alcohol and other CNS depressants
Evaluation: Assess symptom relief and adverse effects regularly
Patient/Family Teaching
- Take exactly as prescribed or directed on the label
- Avoid alcohol and sedatives during therapy
- Caution when driving or operating machinery
- Notify healthcare provider if experiencing excessive drowsiness, confusion, or allergic reactions
Special Considerations
Black Box Warnings:
- Potential for severe CNS depression in children, especially under 2 years old
Genetic Factors: CYP2D6 metabolizer status may affect drug levels
Lab Test Interference: May interfere with certain skin allergy and other tests
Overdose Management
Signs/Symptoms: Extreme sedation, agitation, hallucinations, seizures, tachycardia, dry mouth, urinary retention, hypo- or hypertension
Treatment: Supportive care, activated charcoal if within 1 hour of ingestion, physostigmine in severe anticholinergic toxicity, airway management, hemodynamic support as needed
Storage and Handling
Storage: Store at room temperature between 20-25°C (68-77°F), away from moisture and light
Stability: Stable under recommended storage conditions for the duration of the labeled shelf life